The global human papilloma virus testing market is expected to witness lucrative growth over the forecast period owing to the increasing prevalence of cervical cancer. The rise in the global geriatric female population is also one of the key drivers for market growth due to the presence of co-morbidities in elderly females. Human papilloma virus is one of the leading causes of cancer worldwide. Hence, there is a rising need for innovation in diagnostics to detect human papilloma virus (HPV) associated cancer. Hence, other factors that drive the HPV testing market are increasing awareness about the link between human papilloma virus and cervical cancer coupled with the unmet need for accuracy in diagnostic testing. Failure of human papilloma virus detection by primary screening tests due to less sensitivity and false-negative results makes a positive impact on the market for human papilloma virus testing. Moreover, available human papilloma virus vaccination cannot preclude the female population from cervical cancer and this continues to spur the growth of the market even amongst the human papilloma virus vaccinated women.
The human papilloma virus testing market is segmented on the basis of types and applications. The types segment is bifurcated into high-risk human papilloma virus and low-risk human papilloma virus. Amongst the two segments, high-risk human papillomavirus held a larger market share in 2014 owing to the presence of laboratory conducting and screening tests. On the basis of applications, the market can be classified as immunoassays, monoclonal and polyclonal antibodies, microarrays, molecular diagnostics, chromosome analysis, flow cytometry, artificial intelligence, microcomputers, and biosensors. Molecular diagnostics held the largest market share in 2014 owing to the inability of human papilloma virus to be cultured in the laboratory which is a prerequisite for the growth of other segments. The other factors responsible for the highest share of molecular diagnostics in 2014 are the identification of many unique types of high-risk human papilloma virus by molecular diagnostic tests, which can lead to better diagnosis and treatment plans for patients. Molecular diagnostics is expected to be the fastest-growing segment over the forecast period due to various reasons such as the possibility for target amplification, probe amplification, and signal amplification in the detection and screening of human papilloma virus. Introduction of automated methodology with faster turnaround time, quality patient care at a reasonable cost, along with accurate and true positive results are the other factors that can lead to the dominance of molecular diagnostics segment in the HPV testing market.
Geographically, the human papilloma virus testing market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA. North America held a substantial share in the market in 2014. The major factors that attributed to the high share of North America include the increased prevalence of cancer coupled with the early diagnosis and treatment awareness programs carried out by the government. Asia Pacific is expected to be the fastest-growing region in the market over the forecast period owing to the increasing prevalence of cervical cancer and other sexually transmitted diseases like chancroid, HSV, and HIV. Advancements in highly specific screening assays, for identification of actual disease rather than the risk of predisposition to disease, may also lead to spur regional growth of market. Rise in the mortality rate due to human papilloma virus transmission and infection is also one of the factors that are anticipated to boost substantial growth of this region in the market in the coming seven years.
The prominent players in human papilloma virus testing market are Abbott, Biomedical Diagnostics, bioMerieux, CanAG Diagnostics, CeMines, Bio-Rad, Epigenomics, Fujirebio, Guided Therapeutics, Ipsogen, J&J Diagnostics, Gen-Probe, OncoLab, Hologic, Polartechnics, Qiagen, Radient, Pharmaceuticals, Roche, Sequenom, Targeted Diagnostics & Therapeutics, and Siemens Healthcare. The market strategies of the competitors include the innovative awareness programs coupled with the treatment regimens such as vaccination and monoclonal antibodies. Market players are adopting and complying with new guidelines for cervical screening to maintain and enhance their position in the market.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPA norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.